Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients-authors' response.

IF 3.9 2区医学 Q1 INFECTIOUS DISEASES

Journal of Antimicrobial Chemotherapy Pub Date : 2024-10-07 DOI:10.1093/jac/dkae357

Tzong-Yow Wu, Pao-Yu Chen, Jann-Tay Wang, Wang-Da Liu, Yee-Chun Chen, Shan-Chwen Chang

引用次数: 0

查看原文本刊更多论文

免疫功能低下患者持续感染 SARS-CoV-2 后，对替卡西单抗/西格维单抗和雷米替韦联合疗法的反应不理想--作者的回应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Antimicrobial Chemotherapy 医学-传染病学

CiteScore

9.20

自引率

5.80%

发文量

423

审稿时长

2-4 weeks

期刊介绍： The Journal publishes articles that further knowledge and advance the science and application of antimicrobial chemotherapy with antibiotics and antifungal, antiviral and antiprotozoal agents. The Journal publishes primarily in human medicine, and articles in veterinary medicine likely to have an impact on global health.